NCT00033956View on ClinicalTrials.gov

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2001

Conditions
IL-2 Induced Hypotension
Interventions
DRUG

M40403

Trial Locations (3)

84112

Huntsman Cancer Institute, Salt Lake City

60611-2927

Northwestern University Medical School, Chicago

97213-3635

Providence Portland Medical Center, Portland

Sponsors
All Listed Sponsors
lead

MetaPhore Pharmaceuticals

INDUSTRY